NASDAQ:SCMP - Sucampo Pharmaceuticals Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $18.00 0.00 (0.00 %) (As of 07/22/2018 08:34 AM ET)Previous Close$18.00Today's Range$18.00 - $18.0052-Week Range$9.30 - $18.75Volume303,068 shsAverage Volume2.56 million shsMarket Capitalization$839.46 millionP/E RatioN/ADividend YieldN/ABeta1.38 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product. VTS-270 is an investigational drug under clinical study for the treatment of Niemann-Pick Disease Type C-1, an ultra-orphan, progressive and fatal disease. AMITIZA is a ClC-2 chloride channel activator, which has been approved for three indications that cover distinct patient types: chronic idiopathic constipation, irritable bowel syndrome with constipation, and opioid-induced constipation. RESCULA is a Big Potassium channel activator used to lower intraocular pressure. CPP-1X/sulindac combination product is meant for the treatment of familial adenomatous polyposis (FAP). Receive SCMP News and Ratings via Email Sign-up to receive the latest news and ratings for SCMP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryPharmaceuticals SectorN/A SymbolNASDAQ:SCMP CUSIP86490910 Webwww.sucampo.com Phone+1-301-9613400 Debt Debt-to-Equity Ratio7.37 Current Ratio5.11 Quick Ratio4.46 Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio16.07 P/E Growth5.06 Sales & Book Value Annual Sales$230.06 million Price / Sales3.69 Cash Flow$2.4096 per share Price / Cash7.47 Book Value$3.60 per share Price / Book5.00 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$18.48 million Net Margins16.92% Return on Equity126.04% Return on Assets11.04% Miscellaneous Employees139 Outstanding Shares47,170,000Market Cap$839.46 Sucampo Pharmaceuticals (NASDAQ:SCMP) Frequently Asked Questions What is Sucampo Pharmaceuticals' stock symbol? Sucampo Pharmaceuticals trades on the NASDAQ under the ticker symbol "SCMP." How were Sucampo Pharmaceuticals' earnings last quarter? Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) posted its earnings results on Wednesday, November, 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.02. The biopharmaceutical company had revenue of $61.27 million for the quarter, compared to analyst estimates of $58.05 million. Sucampo Pharmaceuticals had a net margin of 16.92% and a return on equity of 126.04%. The company's revenue for the quarter was up 5.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.30 EPS. View Sucampo Pharmaceuticals' Earnings History. What price target have analysts set for SCMP? 8 Wall Street analysts have issued 12-month price objectives for Sucampo Pharmaceuticals' shares. Their forecasts range from $15.00 to $43.00. On average, they expect Sucampo Pharmaceuticals' share price to reach $22.8750 in the next year. This suggests a possible upside of 27.1% from the stock's current price. View Analyst Ratings for Sucampo Pharmaceuticals. What is the consensus analysts' recommendation for Sucampo Pharmaceuticals? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sucampo Pharmaceuticals in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." What are Wall Street analysts saying about Sucampo Pharmaceuticals stock? Here are some recent quotes from research analysts about Sucampo Pharmaceuticals stock: 1. According to Zacks Investment Research, "Sucampo’s pending acquisition by Mallinckrodt for $1.2 billion have raised investor concerns that the latter may be underpaying for the company. A sNDA for label expansion of Amitizia in pediatric functional constipation is under review. Also, Sucampo’s collaborations with firms like Takeda and Mylan for Amitiza’s commercialization is a big positive. Moreover, the Vtesse acquisition added a pivotal program in Niemann-Pick Disease type C1 to its pipeline. However, Sucampo’s dependence on Amitiza for growth is concerning with few companies trying to market and sell generic version of Amitiza. Moreover, Sucampo discontinued Amitzia’s sprinkle formulation development as it did not meet bioequivalence with capsule formulation. Shares of the company have outperformed the industry. Estimates have remained stable ahead of the Q4 earnings results. The company has a mixed record of earnings surprises in recent quarters." (2/9/2018) 2. Maxim Group analysts commented, "Sucampo’s stock has risen sharply in the past few weeks (from ~$10 to $16+) on no new fundamental news. However, a Bloomberg story has been circulating that the company may be entertaining suitors. We have no specific knowledge to confirm this, but do see an undervalued company that is generating free cash flow and has a strong (orphan) pipeline. Our last note (from 11/21) reviewed the R&D Day which focused on two key pipeline products, VTS-270 (Neeman Pick Disease) and CPP-1X/sulindac (Familial Adenomatous Polyposis )." (12/7/2017) Who are Sucampo Pharmaceuticals' key executives? Sucampo Pharmaceuticals' management team includes the folowing people: Peter S. Greenleaf, Chairman of the Board, Chief Executive Officer (Age 47)Peter P. Pfreundschuh CPA, Chief Financial Officer (Age 48)Max Donley, Executive Vice President of Global Human Resources, Information Technology and Strategy (Age 48)Matthias Alder, Executive Vice President (Age 52)Peter A. Kiener Ph.D., Chief Scientific Officer (Age 64)Alex Driggs, General Counsel, Corporate Secretary (Age 41)Peter Lichtlen M.D., Ph.D., Chief Medical Officer (Age 47)John H. Johnson, Lead Independent Director (Age 58)Paul R. Edick, Director (Age 62)Daniel P. Getman Ph.D., Director (Age 59) Has Sucampo Pharmaceuticals been receiving favorable news coverage? News coverage about SCMP stock has trended somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Sucampo Pharmaceuticals earned a coverage optimism score of 0.01 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 45.92 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term. How do I buy shares of Sucampo Pharmaceuticals? Shares of SCMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Sucampo Pharmaceuticals' stock price today? One share of SCMP stock can currently be purchased for approximately $18.00. How big of a company is Sucampo Pharmaceuticals? Sucampo Pharmaceuticals has a market capitalization of $839.46 million and generates $230.06 million in revenue each year. Sucampo Pharmaceuticals employs 139 workers across the globe. How can I contact Sucampo Pharmaceuticals? Sucampo Pharmaceuticals' mailing address is 805 King Farm Blvd Ste 550, ROCKVILLE, MD 20850-6162, United States. The biopharmaceutical company can be reached via phone at +1-301-9613400 or via email at [email protected] MarketBeat Community Rating for Sucampo Pharmaceuticals (NASDAQ SCMP)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 271 (Vote Outperform)Underperform Votes: 241 (Vote Underperform)Total Votes: 512MarketBeat's community ratings are surveys of what our community members think about Sucampo Pharmaceuticals and other stocks. Vote "Outperform" if you believe SCMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCMP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/22/2018 by MarketBeat.com StaffFeatured Article: What are CEFs?